OncoMatch/Clinical Trials/NCT06565247
Evaluation of PSMA-PET and mpMRI in High-risk Prostate Cancer - Using Histopathologic Validation
Is NCT06565247 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies multiple treatments including [18F]PSMA-PET and MRI sequences optimized for prostate cancer examinations for prostate cancer.
Treatment: [18F]PSMA-PET · MRI sequences optimized for prostate cancer examinations — In this trial the connection between image properties (mpMRI and PSMA-PET) and tissue properties (molecular and histopathology) will be investigated in order to improve diagnostics and image-based treatment guidance of prostate cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
WHO 0–1
Demographics
Prior therapy
Cannot have received: antiandrogen
Patients treated with neoadjuvant/concomitant anti-testosterone treatment (surgical or medical castration or anti-androgens)
Cannot have received: transurethral resection of the prostate
TUR-P within 6 months
Lab requirements
Kidney function
Creatinine clearance < 30ml/min [excluded]
Creatinine clearance < 30ml/min (acc. to http://www.fass.se/LIF/produktfakta-/kreatinin.jsp)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06565247 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior antiandrogen, transurethral resection of the prostate disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages